Back

Targeting host deoxycytidine kinase attenuates Staphylococcus aureus virulence

Winstel, V.; Abt, E. R.; Radu, C. G.

2023-08-18 microbiology
10.1101/2023.08.18.553822 bioRxiv
Show abstract

Host-directed therapy (HDT) is an emerging approach to overcome antimicrobial resistance in pathogenic microorganisms. Specifically, HDT targets host-encoded factors required for pathogen replication and survival without interfering with microbial growth or metabolism, thereby eliminating the risk of resistance development. By applying HDT and a drug repurposing approach, we demonstrate that (R)-DI-87, a clinical-stage anti-cancer drug and potent inhibitor of mammalian deoxycytidine kinase (dCK), mitigates Staphylococcus aureus abscess formation in organ tissues upon invasive bloodstream infection. Mechanistically, (R)-DI-87 shields phagocytes from staphylococcal death-effector deoxyribonucleosides that target dCK and the mammalian purine salvage pathway-apoptosis axis. In this manner, (R)-DI-87-mediated protection of immune cells amplifies macrophage infiltration into deep-seated abscesses, a phenomenon coupled with enhanced pathogen control, ameliorated immunopathology, and reduced disease severity. Thus, pharmaceutical blockade of dCK represents an advanced anti-infective intervention strategy against which staphylococci cannot develop resistance and may help to fight fatal infectious diseases in hospitalized patients.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 1%
26.2%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 7%
5.4%
Similar papers in this journal
3
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 10%
5.1%
Similar papers in this journal
4
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
4.8%
Similar papers in this journal
5
mBio
● 833 papers in training set
Top 4%
4.0%
Similar papers in this journal
6
Journal of Clinical Investigation
● 179 papers in training set
Top 1%
3.4%
7
Cell Death & Disease
147 papers in training set
Top 0.9%
3.2%
50% of probability mass above
8
iScience
○ 1154 papers in training set
Top 8%
3.1%
9
Scientific Reports
○ 3612 papers in training set
Top 37%
2.8%
10
Nature Communications
○ 5641 papers in training set
Top 39%
2.4%
11
Cell Chemical Biology
○ 94 papers in training set
Top 0.5%
2.4%
12
Frontiers in Immunology
○ 638 papers in training set
Top 5%
2.1%
13
ACS Infectious Diseases
● 82 papers in training set
Top 0.7%
2.1%
14
PLOS Pathogens
● 820 papers in training set
Top 5%
2.1%
15
Cell Reports Medicine
○ 153 papers in training set
Top 2%
1.9%
16
The EMBO Journal
○ 309 papers in training set
Top 3%
1.7%
17
Cell Death & Differentiation
○ 48 papers in training set
Top 0.5%
1.7%
18
Cell Death Discovery
○ 58 papers in training set
Top 0.7%
1.5%
19
Journal of Biological Chemistry
○ 690 papers in training set
Top 7%
1.3%
20
Frontiers in Cellular and Infection Microbiology
○ 109 papers in training set
Top 2%
1.1%
21
Antimicrobial Agents and Chemotherapy
● 187 papers in training set
Top 2%
1.1%
22
Gut Microbes
○ 78 papers in training set
Top 1%
1.0%
23
Science Translational Medicine
● 127 papers in training set
Top 4%
0.8%
24
JCI Insight
● 277 papers in training set
Top 8%
0.8%
25
PLOS Biology
● 486 papers in training set
Top 12%
0.8%
26
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
0.8%
27
Communications Biology
○ 993 papers in training set
Top 31%
0.8%
28
EMBO Reports
○ 263 papers in training set
Top 7%
0.8%
29
International Journal of Molecular Sciences
○ 494 papers in training set
Top 18%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.